SCHEMBL6946029

SCHEMBL6946029

CS(=O)(=O)OCc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.48
ACHE P22303 1/20 0.48
KIF11 P52732 1/20 0.47
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP14 P50281 1/20 0.45
ADAM17 P78536 1/20 0.45
KMT2A Q03164 1/20 0.44
CNR2 P34972 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
PTPRZ1 P23471 1/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26962055 0.85 PTGES2 (0.43) BCHEACHEKIF11MMP14KMT2A
SCHEMBL5903752 0.83 BCHE (0.46) BCHEACHEKIF11CNR2ALDH1A1
SCHEMBL4952656 0.81 CA2 (0.58) MMP9KMT2AALDH1A1TSHRCA2
SCHEMBL18002165 0.81 NR3C1 (0.49) MMP2MMP9MMP14ADAM17CHRM5
SCHEMBL6620322 0.81 BCHE (0.44) BCHEACHEKIF11MMP9CNR2
SCHEMBL8685996 0.79 KMT2A (0.69) BCHEACHEKIF11KMT2ACA2
SCHEMBL514550 0.79 BCHE (0.50) BCHEACHEKIF11MMP1MMP2
SCHEMBL7420399 0.78 CA2 (0.47) MMP1MMP2MMP9MMP14ALDH1A1
SCHEMBL5937187 0.78 APLNR (0.59) CA2CA9CA12CA1PTGS2
SCHEMBL7008210 0.78 KIF11 (0.46) BCHEACHEKIF11MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 WO disclosed
EP-1115729-B1 PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PTP-1B MERCK FROSST CANADA INC (CA) 2003-02-19 EP disclosed
US-6174874-B1 ANTIDIABETIC,-CARCINOGENIC AGENTS; IMPROVING GLUCOSE TOLERANCE/INSULIN-SENSITIVITY; PREVENTING/TREATING OBESITY AND NEURODEGENERATIVE DISEASES; E.G. 1,3-BIS-((PHOSPHONODI-FLUOROMETHYL)PHENYL)-2-DICARBOXYPROPANE MERCK FROSST CANADA & CO. (CA) 2001-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA BCHE 1276/4885ACHE 3394/4885KIF11 4768/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 BCHE 2294/4885ACHE 4101/4885KIF11 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.